SG10201801321XA - Formulations of quinones for the treatment of ophthalmic diseases - Google Patents
Formulations of quinones for the treatment of ophthalmic diseasesInfo
- Publication number
- SG10201801321XA SG10201801321XA SG10201801321XA SG10201801321XA SG10201801321XA SG 10201801321X A SG10201801321X A SG 10201801321XA SG 10201801321X A SG10201801321X A SG 10201801321XA SG 10201801321X A SG10201801321X A SG 10201801321XA SG 10201801321X A SG10201801321X A SG 10201801321XA
- Authority
- SG
- Singapore
- Prior art keywords
- quinones
- formulations
- treatment
- ophthalmic diseases
- ophthalmic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32854610P | 2010-04-27 | 2010-04-27 | |
| US39369310P | 2010-10-15 | 2010-10-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201801321XA true SG10201801321XA (en) | 2018-04-27 |
Family
ID=44861894
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201801321XA SG10201801321XA (en) | 2010-04-27 | 2011-04-26 | Formulations of quinones for the treatment of ophthalmic diseases |
| SG2012079323A SG185046A1 (en) | 2010-04-27 | 2011-04-26 | Formulations of quinones for the treatment of ophthalmic diseases |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2012079323A SG185046A1 (en) | 2010-04-27 | 2011-04-26 | Formulations of quinones for the treatment of ophthalmic diseases |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20130109759A1 (en) |
| EP (1) | EP2563352A4 (en) |
| JP (2) | JP5902673B2 (en) |
| CN (2) | CN102985083A (en) |
| AU (1) | AU2011245384C1 (en) |
| BR (1) | BR112012027543A8 (en) |
| CA (1) | CA2797581A1 (en) |
| EA (1) | EA201201465A1 (en) |
| MX (1) | MX337594B (en) |
| MY (1) | MY183449A (en) |
| SG (2) | SG10201801321XA (en) |
| WO (1) | WO2011137126A1 (en) |
| ZA (1) | ZA201208535B (en) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050065099A1 (en) | 2003-09-19 | 2005-03-24 | Gail Walkinshaw | Treatment of mitochondrial diseases |
| DK1888059T3 (en) | 2005-06-01 | 2015-03-30 | Edison Pharmaceuticals Inc | Redox-active therapeutic products for the treatment of mitochondrial diseases and other conditions as well as modulation of energy biomarkers |
| EP1986636B1 (en) | 2006-02-22 | 2013-04-24 | Edison Pharmaceuticals, Inc. | Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases |
| EA028911B1 (en) | 2007-11-06 | 2018-01-31 | Биоэлектрон Текнолоджи Корпорейшн | 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES |
| US8952071B2 (en) | 2008-01-08 | 2015-02-10 | Edison Pharmaceuticals, Inc. | (Het)aryl-p-quinone derivatives for treatment of mitochondrial diseases |
| EP2262508B1 (en) | 2008-03-05 | 2018-10-03 | BioElectron Technology Corporation | SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES |
| US8716486B2 (en) * | 2008-06-25 | 2014-05-06 | Edison Pharmaceuticals, Inc. | 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases |
| EP3827815B1 (en) | 2008-09-10 | 2023-09-06 | PTC Therapeutics, Inc. | Treatment of pervasive developmental disorders with redox-active therapeutics |
| EP2362726B1 (en) | 2008-10-14 | 2018-08-08 | Bioelectron Technology Corporation | Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells |
| US8106223B2 (en) | 2008-10-28 | 2012-01-31 | Edison Pharmaceuticals, Inc. | Process for the production of alpha-tocotrienol and derivatives |
| MX336800B (en) | 2009-04-28 | 2016-02-02 | Edison Pharmaceuticals Inc | Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones. |
| EA028677B1 (en) * | 2009-08-26 | 2017-12-29 | Биоэлектрон Текнолоджи Корпорейшн | Method for the treatment, prevention and/or amelioration of neuronal damage associated with cerebral ischemia |
| BR112012025558A2 (en) * | 2010-04-06 | 2016-06-28 | Edison Pharmaceuticals Inc | treatment for ataxia-telangiectasia |
| CN102985083A (en) * | 2010-04-27 | 2013-03-20 | 爱迪生药物公司 | Formulations of quinones for the treatment of ophthalmic diseases |
| US9464016B2 (en) | 2011-06-14 | 2016-10-11 | Edison Pharmaceuticals, Inc. | Catechol derivatives for treatment of oxidative stress diseases |
| US9162957B2 (en) | 2011-07-19 | 2015-10-20 | Edison Pharmaceuticals, Inc. | Methods for oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols |
| JP6393684B2 (en) * | 2012-09-07 | 2018-09-19 | バイオエレクトロン テクノロジー コーポレイション | Quinone derivatives for use in regulating the redox state of individuals |
| US9670170B2 (en) | 2013-03-15 | 2017-06-06 | Bioelectron Technology Corporation | Resorufin derivatives for treatment of oxidative stress disorders |
| US9296712B2 (en) | 2013-03-15 | 2016-03-29 | Edison Pharmaceuticals, Inc. | Resorufin derivatives for treatment of oxidative stress disorders |
| US9868711B2 (en) | 2013-03-15 | 2018-01-16 | Bioelectron Technology Corporation | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
| US10189830B2 (en) | 2013-03-15 | 2019-01-29 | Bioelectron Technology Corporation | Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders |
| MX2017008063A (en) | 2014-12-16 | 2017-09-28 | Bioelectron Tech Corp | Polymorphic and amorphous forms of (r)-2-hydroxy-2-methyl-4-(2,4, 5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide. |
| US10745371B2 (en) | 2015-12-16 | 2020-08-18 | Ptc Therapeutics, Inc. | Methods for enriching alpha-tocotrienol from mixed tocol compositions |
| WO2017106803A1 (en) | 2015-12-17 | 2017-06-22 | Bioelectron Technology Corporation | Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
| JP2018083799A (en) | 2016-11-15 | 2018-05-31 | バイオエレクトロン テクノロジー コーポレイション | 2-SUBSTITUTED AMINO-NAPHTHO[1,2-d]IMIDAZOLE-5-ONE COMPOUND OR PHARMACEUTICALLY ALLOWABLE SALTS THEREOF |
| WO2019070917A1 (en) * | 2017-10-03 | 2019-04-11 | The Schepens Eye Research Institute, Inc. | Compounds and compositions for inhibiting retinal pigment epithelium degeneration and methods using the same |
| AU2019362010A1 (en) | 2018-10-17 | 2021-05-20 | Ptc Therapeutics, Inc. | 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating α-synucleinopathies, tauopathies, and other disorders |
| WO2023283466A1 (en) | 2021-07-08 | 2023-01-12 | Ptc Therapeutics, Inc. | Pharmaceutical compositions comprising 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1888059T3 (en) * | 2005-06-01 | 2015-03-30 | Edison Pharmaceuticals Inc | Redox-active therapeutic products for the treatment of mitochondrial diseases and other conditions as well as modulation of energy biomarkers |
| JP5122460B2 (en) * | 2005-09-16 | 2013-01-16 | アラーガン、インコーポレイテッド | Compositions and methods for intraocular delivery of therapeutic agents |
| EP1986636B1 (en) * | 2006-02-22 | 2013-04-24 | Edison Pharmaceuticals, Inc. | Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases |
| EP3827815B1 (en) * | 2008-09-10 | 2023-09-06 | PTC Therapeutics, Inc. | Treatment of pervasive developmental disorders with redox-active therapeutics |
| EA028677B1 (en) * | 2009-08-26 | 2017-12-29 | Биоэлектрон Текнолоджи Корпорейшн | Method for the treatment, prevention and/or amelioration of neuronal damage associated with cerebral ischemia |
| BR112012025558A2 (en) * | 2010-04-06 | 2016-06-28 | Edison Pharmaceuticals Inc | treatment for ataxia-telangiectasia |
| CN102985083A (en) * | 2010-04-27 | 2013-03-20 | 爱迪生药物公司 | Formulations of quinones for the treatment of ophthalmic diseases |
-
2011
- 2011-04-26 CN CN2011800317444A patent/CN102985083A/en active Pending
- 2011-04-26 BR BR112012027543A patent/BR112012027543A8/en not_active IP Right Cessation
- 2011-04-26 CA CA2797581A patent/CA2797581A1/en not_active Abandoned
- 2011-04-26 MX MX2012012518A patent/MX337594B/en active IP Right Grant
- 2011-04-26 SG SG10201801321XA patent/SG10201801321XA/en unknown
- 2011-04-26 CN CN201510490746.XA patent/CN105147651A/en active Pending
- 2011-04-26 MY MYPI2012004738A patent/MY183449A/en unknown
- 2011-04-26 EA EA201201465A patent/EA201201465A1/en unknown
- 2011-04-26 US US13/643,542 patent/US20130109759A1/en not_active Abandoned
- 2011-04-26 EP EP11775506.6A patent/EP2563352A4/en not_active Withdrawn
- 2011-04-26 AU AU2011245384A patent/AU2011245384C1/en not_active Ceased
- 2011-04-26 WO PCT/US2011/033983 patent/WO2011137126A1/en active Application Filing
- 2011-04-26 JP JP2013508167A patent/JP5902673B2/en not_active Expired - Fee Related
- 2011-04-26 SG SG2012079323A patent/SG185046A1/en unknown
-
2012
- 2012-11-13 ZA ZA2012/08535A patent/ZA201208535B/en unknown
-
2016
- 2016-03-10 JP JP2016046881A patent/JP6266674B2/en not_active Expired - Fee Related
-
2017
- 2017-01-17 US US15/407,831 patent/US20170354618A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2012012518A (en) | 2012-12-17 |
| CN102985083A (en) | 2013-03-20 |
| AU2011245384C1 (en) | 2016-09-01 |
| EP2563352A1 (en) | 2013-03-06 |
| EA201201465A1 (en) | 2013-04-30 |
| MX337594B (en) | 2016-03-11 |
| AU2011245384A1 (en) | 2012-12-06 |
| BR112012027543A2 (en) | 2019-05-28 |
| SG185046A1 (en) | 2012-12-28 |
| EP2563352A4 (en) | 2013-11-13 |
| MY183449A (en) | 2021-02-18 |
| WO2011137126A1 (en) | 2011-11-03 |
| JP6266674B2 (en) | 2018-01-24 |
| CA2797581A1 (en) | 2011-11-03 |
| CN105147651A (en) | 2015-12-16 |
| BR112012027543A8 (en) | 2019-12-03 |
| US20130109759A1 (en) | 2013-05-02 |
| AU2011245384B2 (en) | 2016-02-18 |
| US20170354618A1 (en) | 2017-12-14 |
| JP2016106144A (en) | 2016-06-16 |
| JP2013525443A (en) | 2013-06-20 |
| JP5902673B2 (en) | 2016-04-13 |
| ZA201208535B (en) | 2016-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201208535B (en) | Formulations of quinones for the treatment of ophthalmic diseases | |
| ZA201403795B (en) | Formulations for the treatment of diabetes | |
| EP2621499A4 (en) | Methods for the treatment of allergic diseases | |
| HUE041553T2 (en) | Methods and compositions for the treatment of monogenic diseases | |
| EP2740482A4 (en) | Prophylactic or therapeutic agent for oral diseases | |
| ZA201301601B (en) | Treatment of diseases | |
| PL2925757T3 (en) | Compounds and compositions for the treatment of parasitic diseases | |
| EP2613786A4 (en) | Treatment of diseases | |
| GB2479213B (en) | Pharmaceutical formulations for the treatment of overactive bladder | |
| GB201021103D0 (en) | New compounds for the treatment of neurodegenerative diseases | |
| HK1186671A1 (en) | Formulations for the treatment of disorders of the upper respiratory tract | |
| IL275350B (en) | Treatment for neoplastic diseases | |
| EP2623494A4 (en) | Agent for treatment of eye diseases | |
| GB0906159D0 (en) | Drug combination for the treatment of proteostatic diseases | |
| ZA201305970B (en) | Arylosulfonami for the treatment of cns diseases | |
| EP2709632A4 (en) | Compositions and methods for the treatment of skin diseases | |
| SI2605769T1 (en) | Benzoquinone derivatives for the treatment of mitchondrial eye diseases | |
| EP2723325A4 (en) | Novel formulations and methods for treating dermatological disorders or diseases | |
| GB201114289D0 (en) | Flurbiprofen and related compounds for the treatment of skin diseases | |
| HK1214771A1 (en) | Formulations for use in the treatment of skin conditions | |
| EP2599776A4 (en) | Therapeutic agent for neurological diseases | |
| HK1196953A1 (en) | Formulations for the treatment of diabetes | |
| GB0901727D0 (en) | The treatment of ophthalmic diseases | |
| AU2011903764A0 (en) | Treatment of bone diseases | |
| HK1157189A1 (en) | Pharmaceutical composition for the treatment of tumor diseases |